DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
271	強直性脊椎炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03639740 (ClinicalTrials.gov)	January 15, 2019	17/8/2018	Treat-to-target With Secukinumab in Axial Spondyloarthritis	TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)	Axial Spondyloarthritis;Ankylosing Spondylitis	Drug: Secukinumab 150 milligram [Cosentyx]	Professor Mikkel Østergaard	Novartis Healthcare A/S	Recruiting	18 Years	70 Years	All	88	Phase 4	Denmark

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03639740
(ClinicalTrials.gov)

January 15, 2019

17/8/2018

Treat-to-target With Secukinumab in Axial Spondyloarthritis

TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)

Axial Spondyloarthritis;Ankylosing Spondylitis

Drug: Secukinumab 150 milligram [Cosentyx]

Professor Mikkel Østergaard

Novartis Healthcare A/S

Recruiting

18 Years

70 Years

All

Phase 4

Denmark